Europe Immunoglobulin Market Forecast 2022-2030

Europe Immunoglobulin Market Forecast 2022-2030

KEY FINDINGS

The Europe immunoglobulin market is predicted to progress with a CAGR of 6.90% across the forecast period of 2022 to 2030. The regional market’s growth is fuelled by supportive government initiatives for immunoglobulin and plasma donation, the prevalence of different immunodeficiency diseases, and the growth of the biotechnology industry.

MARKET INSIGHTS

The Europe immunoglobulin market growth evaluation entails the study of the United Kingdom, Italy, Nordic Countries, France, Germany, Spain, and Rest of Europe. The increasing investments by key players as well as industry giants, primarily for vaccine development and research, is one of the major drivers anticipated to strengthen the growth of the immunoglobulin market in France during the forecast years. In this regard, Pfizer announced its plans to include a production facility for an antiviral COVID-19 drug in the country in 2022. It also entails an investment of $594 million in France over the period of the next five years. Similarly, in 2020, AstraZeneca announced an investment of $520 million in the country within the spectrum of manufacturing, research, and development.

On the other hand, in 2019, Spain-based Grifols announced the approval from the United States Food and Drug Administration (FDA) for Xembify®, the company’s first 20% subcutaneous immunoglobulin for treating primary immunodeficiencies. The product represents a substantial research and development milestone for Grifols, as well as a critical step for its long-term sustainable growth strategy. Therefore, the abovementioned factors are estimated to propel the Europe immunoglobulin market growth over the forecast years.

COMPETITIVE INSIGHTS

The top companies operating in the market include LFB Group, Biotest AG, Grifols SA, etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments


1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations
2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview
3. Market Dynamics
3.1. Key Drivers
3.1.1. Growth In Geriatric Population
3.1.2. Prevalence Of Immunodeficiency Diseases And Autoimmune Disorders
3.1.3. Increasing Research And Development Activities
3.2. Key Restraints
3.2.1. High Cost Of Therapy
3.2.2. High Risk Of Side Effects
4. Key Analytics
4.1. Impact Of Covid-19 On Immunoglobulin Market
4.2. Key Market Trends
4.3. Porter’s Five Forces Analysis
4.3.1. Buyers Power
4.3.2. Suppliers Power
4.3.3. Substitution
4.3.4. New Entrants
4.3.5. Industry Rivalry
4.4. Opportunity Matrix
4.5. Vendor Landscape
4.6. Key Buying Criteria
4.6.1. Source
4.6.2. Application
4.6.3. Epitope
4.6.4. Validation
5. Market By Product
5.1. Igg
5.2. Iga
5.3. Igm
5.4. Ige
5.5. Igd
6. Market By Mode Of Delivery
6.1. Intravenous Immunoglobulin
6.2. Subcutaneous Immunoglobulin
6.3. Intramuscular Immunoglobulin
7. Market By Application
7.1. Hypogamma Globulinemia
7.2. Chronic Inflammatory Demyelinating Polyneuropathy
7.3. Primary Immunodeficiency Diseases
7.4. Myasthenia Gravis
7.5. Multifocal Motor Neuropathy
7.6. Idiopathic Thrombocytopenic Purpura (Itp)
7.7. Inflammatory Myopathies
7.8. Specific Antibody Deficiency
7.9. Guillain-barre Syndrome
7.10. Other Applications
8. Market By Distribution Channel
8.1. Hospital Pharmacy
8.2. Specialty Pharmacy
8.3. Other Distribution Channels
9. Market By End-user
9.1. Hospitals & Clinics
9.2. Homecare
10. Geographical Analysis
10.1. Europe
10.1.1. Market Size & Estimates
10.1.2. Key Growth Enablers
10.1.3. Key Challenges
10.1.4. Key Players
10.1.5. Country Analysis
10.1.5.1. United Kingdom
10.1.5.2. Germany
10.1.5.3. France
10.1.5.4. Spain
10.1.5.5. Italy
10.1.5.6. Nordic Countries
10.1.5.7. Rest Of Europe
11. Competitive Landscape
11.1. Key Strategic Developments
11.1.1. Mergers & Acquisitions
11.1.2. Product Launches & Developments
11.1.3. Partnerships & Agreements
11.1.4. Business Expansions & Divestitures
11.2. Company Profiles
11.2.1. Adma Biologics
11.2.2. Bio Products Laboratory
11.2.3. Biotest Ag
11.2.4. China Biologic Products Inc
11.2.5. Csl Behring
11.2.6. Grifols Sa
11.2.7. Kamada Ltd
11.2.8. Kedrion Biopharma
11.2.9. Lfb Group
11.2.10. Octapharma Ag
11.2.11. Pfizer Inc
11.2.12. Sanquin Plasma Products Bv
11.2.13. Shanghai Raas Blood Products Co Ltd
11.2.14. Sichuan Yuanda Shuyang Pharmaceutical Co Ltd
11.2.15. Takeda Pharmaceutical Company Limited

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings